G. Cavalletti

PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study

G. Marfia, M. Rovaris, M. Filippi, 2021, Journal of Neurology.

Organic cation transporter 2 mRNA expression in dorsal root ganglia neurons

G. Nicolini, R. Rigolio, G. Tredici, 2010 .

Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

G. Marfia, M. Trojano, P. Bramanti, 2024, Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics.